Kairos Pharma, Ltd. (KAPA)
Automate Your Wheel Strategy on KAPA
With Tiblio's Option Bot, you can configure your own wheel strategy including KAPA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KAPA
- Rev/Share 0.0
- Book/Share 0.3484
- PB 2.5129
- Debt/Equity 0.0
- CurrentRatio 7.1583
- ROIC -0.7589
- MktCap 18161166.0
- FreeCF/Share -0.3103
- PFCF -3.3997
- PE -3.1989
- Debt/Assets 0.0
- DivYield 0
- ROE -0.8873
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline
Published: July 28, 2025 by: Newsfile Corp
Sentiment: Neutral
Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers. Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc. , is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality.
Read More
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,” and will be presented on June 2. John Yu, M.D., Kairos C.
Read More
About Kairos Pharma, Ltd. (KAPA)
- IPO Date 2024-09-16
- Website https://kairospharma.com
- Industry Biotechnology
- CEO John S. Yu
- Employees 1